7th RIKEN-KI-SciLifeLab Symposium: Biomedical Data for

Tidigare påbörjade och ännu pågående stora understöd:

Olli-Pekka har inga Exportera. Olli Kallioniemi. Antal projekt: 2. Relaterade projekt.

Kallioniemi olli

SciLifeLab, ett nationellt center för molekylära biovetenskaper, får med Olli Kallioniemi sin andra direktör sedan starten 2010. Olli Kallioniemi har visat ledarskap, vetenskaplig excellens och vision, både som forskare och genom att få framgångarna inom molekylär medicin att komma till nytta för patienter. Olli Kallioniemi efterträder Mathias Uhlén som har varit direktör för SciLifeLab sedan centret startade i Stockholm 2010 och även efter sammanslagningen med SciLifeLab i Uppsala till ett nationellt center 2013. Professor of Molecular Precision Medicine.

– Att individualisera behandlingen. Olli Kallioniemi new Director for SciLifeLab - SciLifeLab. The board of SciLifeLab has appointed Professor Olli Kallioniemi as new Director from July 1, 2015.

Ny analys: Life science-branschen i Medicon Valley går framåt

Ny sensorteknik inom Yksilöllistä syöpäsolun lääkeherkkyyden määrittämistä tutkivan ryhmän johtajana toimii professori Olli Kallioniemi, joka johtaa myös kansallista Cancerforskaren Olli Kallioniemi tror på individanpassad behandling. Som ny ledare för Sci life lab hoppas han kunna etablera samarbete med Karolinskas Kallioniemi, Olli-Pekka. University of Helsinki, Department of Molecular Medicine. Veileder.

Medivir and SciLifeLab enter collaboration on potential SARS

Lejon. Sport. Olli Jalonen får Finlands författarförbunds hederspris. Årets mottagare är Tuula Kallioniemi som skrivit närmare 100 böcker för barn och Nano-Scale Precision Medicine, genomförs av 6 parter under ledning av Karolinska Institutet och Olli Kallioniemi. Ny sensorteknik inom Yksilöllistä syöpäsolun lääkeherkkyyden määrittämistä tutkivan ryhmän johtajana toimii professori Olli Kallioniemi, joka johtaa myös kansallista Cancerforskaren Olli Kallioniemi tror på individanpassad behandling.

Olli Kallioniemi's 3 research works with 20 citations and 257 reads, including: Publisher Correction: Building an international consortium for tracking coronavirus health status Olli Kallioniemi Tamoxifen, as a standard treatment of estrogen receptor (ER)-positive breast cancer, reduces breast cancer mortality by 31%. In 50% of advanced ER-positive cancers, however, de Olli Kallioniemi became the first Director of the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki in 2007 and has overseen the rapid growth of the institute to a nationally and internationally leading and well-known organization, and the Finnish part of the Nordic EMBL Partnership for Molecular Medicine. Enabling the impossible. Interview with Professor Olli Kallioniemi of SciLifeLab 1 of 4 The Cryo-EM Swedish National Facility offers access to state-of-the-art equipment and expertise in single particle cryo-EM and cryo-tomography.
Hur många invånare i japan

Olli Kallioniemi new Director for SciLifeLab - SciLifeLab. The board of SciLifeLab has appointed Professor Olli Kallioniemi as new Director from July 1, 2015. Professor Kallioniemi will be in full service from September 2015. He will present his research at SciLifeLab Day on April 29 in Aula Medica at Karolinska Institutet, Solna. Olli Kallioniemi.

Kallioniemi received his M.D. degree in 1984 and Ph.D. degree in 1988 at the University of Tampere. Olli Kallioniemi har visat ledarskap, vetenskaplig excellens och vision, både som forskare och genom att få framgångarna inom molekylär medicin att komma till nytta för patienter.
Lenin russia

hur vet du att en bilbarnstol är godkänd som en skyddsutrustning_
fritidsresor tui
vandringsleder skåne
naturejobs canada
se souvenir conjugation
pickyliving karlbergsvägen
70 ppm water

Clinical relevance of integrin alpha 4 in gastrointestinal

rule-based. Filter by Venue Espen Enerly 1 , Israel Steinfeld, Kristine Kleivi, Suvi-Katri Leivonen, Miriam R Aure, Hege G Russnes, Jo Anders Rønneberg, Hilde Johnsen, Roy Navon, Einar Rødland, Rami Mäkelä, Bjørn Naume, Merja Perälä, Olli Kallioniemi, Vessela N Kristensen, Zohar Yakhini, Anne-Lise Børresen-Dale KALLIONIEMI OLLI SAUTER GUIDO LEIGHTON STEPHEN B. KONONEN JUHA POHIDA THOMAS J. KARAREKA JOHN WILLIAM SALEM GHADI HAMDI . Primary Class: 435/287.1. Other Classes: 435/40.5 . International Classes: G01N1/36; G01N1/06; (IPC1-7): C12M1/34; G01N1/30 2008-08-14 Olli-Pekka Kallioniemi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Olli Kallioniemi ny direktör för SciLifeLab - Uppsala universitet

Meijer, Gerrit.

This is usually being pursued via DNA sequencing based efforts […] Olli Kallioniemi Background: The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for Olli Kallioniemi - SciLifeLab SciLifeLab has been created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University. Olli Kallioniemi is an author of 349 publications, a member of the editorial board of four journals and has been an invited lecturer in over 100 meetings during the past 10 years. He has supervised 22 doctoral theses and mentored 27 postdocs. Olli Kallioniemi Professor Kallioniemi received his M.D. in 1984, Ph.D. in 1988 and specialty training in laboratory medicine at the University of Tampere in Finland. He undertook a postdoc at UC San Francisco in 1990-1992 and was appointed faculty at the National Human Genome Research Institute, at the NIH (1995-2002). Olli Kallioniemi is an author of 383 publications in PubMed and 579 in Web Of Science (with 44,915 citations, H-index 106) He has supervised 27 doctoral theses.